Cochlear shares hit three-year low on new implant delays

Cochlear shares hit three-year low on new implant delays

The medical device maker expects full-year earnings to land near the bottom end of its forecast range, and has written down its investment in Saluda.

Cochlear (ASX:COH) Down 16% on a Softer Half, What the Market Is Really Pricing

Cochlear had a softer start to its half yearly result, with sales of A$1.1 billion down around 1%. The bigger issue for investors was underlying net profit, which appears to have been the key driver behind the 16% drawdown and the broader selling pressure. Net cash remained solid at A$173 million, although it was down…

Shares in world-leading hearing implant firm hit a low

Cochlear shares have dropped to a three-year low after the hearing implant company delivered weaker-than-expected earnings after its next-generation implant took longer to roll out than anticipated. Cochlear’s statutory net profit for the half-year to December 31 was down 21 per cent to $161.5 million. Net profit excluding one-off items fell 10 per cent to $194.8 million, beneath consensus expectations of $202 million in underlying profit. Cochl…

Cochlear posts modest sales growth but lower profit as Nexa launch continues

Cochlear grows sales revenue but posts lower profit in HY26. Dividend steady as Nexa implant launch impacts result. Read key numbers and outlook.

Cochlear Reports Interim Results: Sales Revenue Up, Net Profit Declines

Cochlear Limited (ASX: COH), a global leader in implantable hearing solutions, today announced its financial results for the half-year ended 31 December 2025. Cochlear provides a range of hearing solutions, including cochlear implants and acoustic implants. The company’s sales revenue saw a modest increase of 1% to $1,176.0 million, up from $1,169.9 million in the prior corresponding period. However, the statutory net profit for the period attri…